AsymBio Wins US$184 Million Funding Round to Back Long-Term Expansion

Asymchem Group (002821.SZ / 6821.HK), together with investors including Hillhouse Qirui, has injected a total of RMB 1.2397 billion (about US$184 million) into its biologics CDMO subsidiary AsymBio. Asymchem contributed RMB 1.05 billion of the new capital. Following the funding, Asymchem's stake in AsymBio increased to 83.4965%. The transaction strengthens the group's strategic position and capital base in outsourced biologics manufacturing, providing a positive catalyst for its A-share and Hong Kong-listed entities.